Characteristic | Number (%) or median (IQR) |
---|---|
Demographic | |
Female gender | 75 (49 %) |
Age (years) | 44 (39.8–48) |
Clinical | |
CD4 count when initially started ART (cells/mm3) (n = 109) | 102 (31–186) |
HIV VL when initially started ART (copies/ml) (n = 100) | 176,893 (73,425–500,000) |
CD4 count when started salvage ART (cells/mm3) (n = 152) | 153 (41–329) |
HIV VL when started salvage ART (copies/ml) (n = 152) | 82,831 (20,060–233,778) |
Number of ART regimens prior to salvage ART | 3 (3–4) |
Known to have originally initiated ART with dual NRTI regimen | 53 (34.9 %) |
Duration of ART exposure prior to salvage ART (years) (n = 122)a | 8.9 (6.9–10.4) |
Duration of PI exposure prior to salvage ART (years) (n = 148)b | 5.1 (3.4–7.2) |
Genotype antiretroviral resistance test (GART)c | |
Thymidine analogue mutationsd, e | |
0 | 45 (30 %) |
1–2 | 35 (23 %) |
≥3 | 72 (47 %) |
Major protease inhibitor mutationsf | |
1–2 | 38 (25 %) |
≥3 | 114 (75 %) |
Stanford resistance scores | |
Lopinavir | 70 (40–90) |
Darunavir | 10 (0–20) |
Etravirineg | 5 (0–15) |
Lopinavir score > 29 (intermediate/high level resistance) | 136 (89.5 %) |
Lopinavir score > 59 (high level resistance) | 88 (57.9 %) |
Darunavir score > 29 (intermediate/high level resistance) | 14 (9.2 %) |
Darunavir score > 59 (high level resistance) | 0 (0.0 %) |
Etravirine score > 29 (intermediate/high level resistance) | 28 (18.4 %) |
Etravirine score > 59 (high level resistance) | 7 (4.6 %) |